Angel initiates Buy on Ipca Labs, sees 30% rise

MUMBAI: Angel Broking has initiated coverage on Ipca Laboratories with a Buy recommendation and expects the stock to touch price target of Rs 505, which is an upside of 30 per cent from current market price of Rs 388 per share.

“Ipca Laboratories is a vertically integrated company with a geographically diversified business model. Ipca has commensurate exposure in its international business with exports to 110 countries accounting for nearly 52% of its top-line in FY2008.

It has grown at steady pace in the past posting a CAGR of 15.7% in net sales and a CAGR of 24.1% in net profit over FY2005-08 primarily driven by its domestic formulations segment. Going forward, we expect the next leg of growth for the company to come from the export segment as it leverages its API capabilities to create a sturdy business in the regulated and emerging formulations market.

We estimate Ipca’s net sales to post a CAGR of 17.4% and adjusted net profit to register CAGR of 15.6% over FY2008-10E. At Rs 390, the stock is trading at 9.1x FY2009E and 6.2x FY2010E Earnings. We believe the stock is trading at attractive valuation compared to its historical trading band of 5-15x. We initiate coverage on the stock, with a Buy recommendation and target price of Rs 505,” the note said.

SOURCE: ECNOMICTIMES

Tags: angel, angel broking, brokerage recommendation, broking, buy, buy rating, ipca labs, target

Similar Posts:

• Buy Ipca Labs, target of Rs 684: Angel Broking
• Buy Sunil Hitech, target of Rs 111: Angel Broking
• Buy Divis Labs, target of Rs 1370: Hem Securities
• Ambit initiates Punj Llyod with “BUY”; target of Rs 110
• Accumulate Crompton Greaves, target of Rs 306: Angel